689258-74-0Relevant academic research and scientific papers
Palladium-catalyzed allylic cross-coupling reactions of primary and secondary homoallylic electrophiles
Stokes, Benjamin J.,Opra, Susanne M.,Sigman, Matthew S.
, p. 11408 - 11411 (2012/09/05)
The Pd(0)-catalyzed allylic cross-coupling of homoallylic tosylate substrates using boronic acids and pinacol esters is reported. The reaction uses 2-(4,5-dihydro-2-oxazolyl)quinoline (quinox) as a ligand and is performed at ambient temperature. The scope of the reaction is broad in terms of both the boronate transmetalating reagent and the substrate and includes secondary tosylates. Mechanistic studies support an alkene-mediated SN2-type stereoinvertive oxidative addition of unactivated primary and secondary alkyl tosylates.
Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization
Nagarajan, Srinivasan R.,Lu, Hwang-Fun,Gasiecki, Alan F.,Khanna, Ish K.,Parikh, Mihir D.,Desai, Bipinchandra N.,Rogers, Thomas E.,Clare, Michael,Chen, Barbara B.,Russell, Mark A.,Keene, Jeffery L.,Duffin, Tiffany,Engleman, V. Wayne,Finn, Mary B.,Freeman, Sandra K.,Klover, Jon A.,Nickols, G. Alan,Nickols, Maureen A.,Shannon, Kristen E.,Steininger, Christina A.,Westlin, William F.,Westlin, Marisa M.,Williams, Melanie L.
, p. 3390 - 3412 (2008/02/08)
The integrin αvβ3 is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal a
Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
-
, (2008/06/13)
The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.
Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
-
Page 74-75, (2010/02/07)
The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.
